Device Trial Radar · NCT05644951
Clinical Trial of EPASS With Hot AXIOS System
Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Dec 23, 2022
Primary completion
Dec 5, 2024
Study completion Aug 29, 2025
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Dec 9, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multi-center, single-arm study for unresectable malignant gastric outlet obstruction with EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS)
Conditions
- Gastric Outlet Obstruction
Interventions
Hot AXIOS system used for EPASSDevice
EUS-guided double-balloon-occluded gastrojejunostomy bypass with Hot AXIOS system
Primary outcomes
What the sponsor says the trial is designed to measure.
- GOOSS 3 rate without MAETime frame: 30 days post index-procedure
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
Teine Keijinkai Hospital
Sapporo, Hokkaido, Japan
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.